Skip to Content
Merck
CN
  • Striatal dopamine homeostasis is altered in mice following Roux-en-Y gastric bypass surgery.

Striatal dopamine homeostasis is altered in mice following Roux-en-Y gastric bypass surgery.

ACS chemical neuroscience (2014-07-30)
India A Reddy, David H Wasserman, Julio E Ayala, Alyssa H Hasty, Naji N Abumrad, Aurelio Galli
ABSTRACT

Roux-en-Y gastric bypass (RYGB) is an effective treatment for obesity. Importantly, weight loss following RYGB is thought to result in part from changes in brain-mediated regulation of appetite and food intake. Dopamine (DA) within the dorsal striatum plays an important role in feeding behavior; we therefore hypothesized that RYGB alters DA homeostasis in this subcortical region. In the current study, obese RYGB-operated mice consumed significantly less of a high-fat diet, weighed less by the end of the study, and exhibited lower adiposity than obese sham-operated mice. Interestingly, both RYGB and caloric restriction (pair feeding) resulted in elevated DA and reduced norepinephrine (NE) tissue levels compared with ad libitum fed sham animals. Consequently, the ratio of NE to DA, a measure of DA turnover, was significantly reduced in both of these groups. The RYGB mice additionally exhibited a significant increase in phosphorylation of tyrosine hydroxylase at position Ser31, a key regulatory site of DA synthesis. This increase was associated with augmented expression of extracellular-signal-regulated kinases ERK1/2, the kinase targeting Ser31. Additionally, RYGB has been shown in animal models and humans to improve insulin sensitivity and glycemic control. Curiously, we noted a significant increase in the expression of insulin receptor-β in RYGB animals in striatum (a glucosensing brain region) compared to sham ad libitum fed mice. These data demonstrate that RYGB surgery is associated with altered monoamine homeostasis at the level of the dorsal striatum, thus providing a critical foundation for future studies exploring central mechanisms of weight loss in RYGB.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
DL-Tyrosine, 99%
Supelco
Ketoprofen, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ketoprofen, United States Pharmacopeia (USP) Reference Standard
Ketoprofen, European Pharmacopoeia (EP) Reference Standard
Supelco
Ketoprofen, VETRANAL®, analytical standard
Sigma-Aldrich
Ketoprofen, meets USP testing specifications
Sigma-Aldrich
Ketoprofen, ≥98% (TLC)
Tyrosine, European Pharmacopoeia (EP) Reference Standard